RecruitingPhase 1NCT04443088

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Sponsor

Shenzhen Ionova Life Sciences Co., Ltd.

Enrollment

78 participants

Start Date

Jun 26, 2020

Study Type

INTERVENTIONAL

Conditions

Cancer Solid Tumor, Adult Cancer, Metastatic Tumor, Solid Solid Carcinoma Solid Tumor, Unspecified, Adult

Summary

Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INV-1120 and Pembrolizumab for people with cancer, cancer, metastatic, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINV-1120

INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.

COMBINATION_PRODUCTPembrolizumab

Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.